Product Information
AUSTEDO XR TITR(12-18-24-30 MG) is a brand product labeled by Teva Neuroscience, Inc., priced at $249.3230 per EA under NDC 68546047729. Its NADAC has been published 40 times since Nov 19, 2025.
FDA first approved this application on Feb 17, 2023.
Manufacturer
Teva Neuroscience, Inc.NDC
68546047729
Classification
Brand
Dosage Form
KIT
Effective Date
1/1/2026
Approval Type
New Drug (NDA)
FDA Application
NDA216354FDA Approved
2/17/2023
On Market Since
7/1/2024
Price Statistics
The NADAC for AUSTEDO XR TITR(12-18-24-30 MG) has been published 40 times since Nov 19, 2025, and over the history we have for it it has risen 5.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $249.3230 per EA |
|---|---|
| All-time high | $249.3230 (Aug 19, 2026) |
| All-time low | $236.3251 (Dec 17, 2025) |
| 52-week high | $249.3230 |
| 52-week low | $236.3251 |
| Median price | $249.3230 |
| Average price | $247.0570 |
| Largest weekly change | +5.5% (Jan 7, 2026) |
| Weeks tracked | 40 |
| Tracking since | Nov 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the deutetrabenazine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of AUSTEDO XR TITR(12-18-24-30 MG)?
The current National Average Drug Acquisition Cost (NADAC) for AUSTEDO XR TITR(12-18-24-30 MG), manufactured by Teva Neuroscience, Inc., is $249.3230 per EA (NDC 68546047729), effective Aug 19, 2026.
How has the price of AUSTEDO XR TITR(12-18-24-30 MG) changed over time?
Over the history we have for it, the NADAC for AUSTEDO XR TITR(12-18-24-30 MG) has risen 5.5%. It has been tracked across 40 weekly CMS publications since Nov 19, 2025.
What are the highest and lowest recorded NADAC prices for AUSTEDO XR TITR(12-18-24-30 MG)?
Since Nov 19, 2025, the NADAC for AUSTEDO XR TITR(12-18-24-30 MG) has ranged from a low of $236.3251 (Dec 17, 2025) to a high of $249.3230 (Aug 19, 2026), with a median of $249.3230 per EA.
Are there cheaper alternatives to AUSTEDO XR TITR(12-18-24-30 MG)?
No other NADAC-published product currently shares the active ingredient and strength of AUSTEDO XR TITR(12-18-24-30 MG) in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AUSTEDO XR TITR(12-18-24-30 MG)?
AUSTEDO XR TITR(12-18-24-30 MG) (NDC 68546047729) is labeled by Teva Neuroscience, Inc., and CMS classifies it as a brand product.